DISCOVERY
Uncover breakthrough
innovations during the drug
discovery phase.
innovations during the drug
discovery phase.
Krista has 20 years of clinical development and operations experience focused on strategic planning and project execution from Phase 1 in healthy volunteers and patients to global Phase 3 studies. Her therapeutic expertise includes oncology in both immunotherapy and chemotherapy, neurodegenerative disease, and pulmonology, including orphan indications and pediatrics. Her product knowledge includes monoclonal antibodies, cell replacement, gene therapy, small molecules, and xenotransplantation.
Over the past 5 years with Halloran Consulting Group, Krista has provided clinical operations department leadership for a variety of clients. Before joining Halloran, Krista held roles of increasing responsibility at the sponsor, CRO, and site levels. At Genzyme Corporation, in addition to managing studies, she led a cross-functional development team through early phase acquisition and subsequent stage gates and participated in task forces for due diligence, protocol feasibility, and case report form design. With the clinical research organization PAREXEL International, she worked as a cross-functional project leader for U.S. and global studies. She also served the site management organization Center for Biomedical Research working with oncology and pulmonology patients and investigators executing Phase I, II, and III studies with over 20 industry sponsors and a variety of CROs, vendors, and systems.
